Loading...
Market
What will be EO-3021's ORR in dose expansion phase by end of 2024?
2
Resolution / Starting Odds
Less than 20% • 25%
20% to 30% • 25%
30% to 40% • 25%
Greater than 40% • 25%
Elevation Oncology's official press releases or clinical trial updates
Story
Elevation Oncology Announces Promising Data from Phase 1 Trial for EO-3021 with 42.8% ORR and 71% DCR
Aug 6, 2024, 11:12 AM
Elevation Oncology has announced promising initial data from its Phase 1 clinical trial evaluating EO-3021 in patients with advanced unresectable or metastatic solid tumors likely to express Claudin 18.2. The trial, which includes patients with gastric and gastroesophageal junction (GEJ) cancers, reported a confirmed overall response rate (ORR) of 42.8% and a disease control rate (DCR) of 71%. The study will now advance to the dose expansion phase. However, the stock price dropped by 40% following the release of the data, which showed an ORR of 20% in a subset of patients, significantly lower than the 47% observed in a previous Chinese study. The data indicated a higher ORR of 43% in patients with Claudin 18.2 expression greater than 20%, compared to the Chinese study's cutoff of greater than 1% expression.
View original story
Similar markets
Less than 30% • 25%
30% to 49% • 25%
50% to 69% • 25%
70% or higher • 25%
Above 55% • 25%
50-55% • 25%
45-50% • 25%
Below 45% • 25%
Yes • 50%
No • 50%
Dose escalation • 25%
Safety assessment • 25%
Efficacy assessment • 25%
Trial termination • 25%
Less than 40% • 25%
40% to 50% • 25%
51% to 60% • 25%
More than 60% • 25%
Meets primary endpoint • 25%
Fails primary endpoint • 25%
Mixed results • 25%
Trial not completed by end of 2025 • 25%
Significant Improvement • 33%
No Change • 33%
Significant Adverse Effects • 34%
Primary endpoint met with significant improvement • 25%
Primary endpoint met with moderate improvement • 25%
Primary endpoint not met • 25%
Trial inconclusive or delayed • 25%
Phase 2 • 25%
Phase 3 • 25%
Trial termination • 25%
No announcement • 25%
Positive results • 25%
Negative results • 25%
Mixed results • 25%
No results announced • 25%
Completed with positive results • 25%
Completed with negative results • 25%
Not completed • 25%
Unknown/Other • 25%